Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial
Marco Valgimigli(University of Bern), David J. Moliterno(University of Kentucky), Ángel Cequier(Bellvitge University Hospital), Edmond Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul W. Armstrong(Canadian VIGOUR Centre), Pierluigi Tricoci(CSL (United States)), Philip E. Aylward(Flinders Medical Centre), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert A. Harrington(Clinical Research Institute), Harvey D. White(University of Auckland), John Strony(University Hospitals of Cleveland), Zhen Huang(Zhejiang Chinese Medical University), Yuliya Lokhnygina(Clinical Research Institute), Petr Widimský(Universidad Americana), Lars Wallentin(Uppsala University), Khaled M. Ziada(Cleveland Clinic)
Cited by 2
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k